TP53, highly frequently mutated gene in HNSCC4, has been an attractive candidate for vaccines potentially capable of inducing immune responses in HNSCC patients directed against tumor-specific antigens. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.